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Abstract
Background: There is increasing interest in the timely administration of concentrated sources of fibrinogen to patients
with major traumatic bleeding. Following evaluation of early cryoprecipitate in the CRYOSTAT 1 trial, we explored the
use of fibrinogen concentrate, which may have advantages of more rapid administration in acute haemorrhage. The
aims of this pragmatic study were to assess the feasibility of fibrinogen concentrate administration within 45 minutes
of hospital admission and to quantify efficacy in maintaining fibrinogen levels ≥ 2 g/L during active haemorrhage.
Methods: We conducted a blinded, randomised, placebo-controlled trial at five UK major trauma centres with adult
trauma patients with active bleeding who required activation of the major haemorrhage protocol. Participants were
randomised to standard major haemorrhage therapy plus 6 g of fibrinogen concentrate or placebo.
Results: Twenty-seven of 39 participants (69%; 95% CI, 52–83%) across both arms received the study intervention
within 45 minutes of admission. There was some evidence of a difference in the proportion of participants with
fibrinogen levels ≥ 2 g/L between arms (p = 0.10). Fibrinogen levels in the fibrinogen concentrate (FgC) arm rose by
a mean of 0.9 g/L (SD, 0.5) compared with a reduction of 0.2 g/L (SD, 0.5) in the placebo arm and were significantly
higher in the FgC arm (p < 0.0001) at 2 hours. Fibrinogen levels were not different at day 7. Transfusion use and
thromboembolic events were similar between arms. All-cause mortality at 28 days was 35.5% (95% CI, 23.8–50.8%)
overall, with no difference between arms.
Conclusions: In this trial, early delivery of fibrinogen concentrate within 45 minutes of admission was not feasible.
Although evidence points to a key role for fibrinogen in the treatment of major bleeding, researchers need to
recognise the challenges of timely delivery in the emergency setting. Future studies must explore barriers to rapid
fibrinogen therapy, focusing on methods to reduce time to randomisation, using ‘off-the-shelf’ fibrinogen therapies
(such as extended shelf-life cryoprecipitate held in the emergency department or fibrinogen concentrates with very
rapid reconstitution times) and limiting the need for coagulation test-based transfusion triggers.
Trial registration: ISRCTN67540073. Registered on 5 August 2015.
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Background
Uncontrolled bleeding is the most common preventable
cause of death in major trauma [1]; it affects up to 40% of
patients with severe injury. Trauma haemorrhage is exac-
erbated by a complex interplay of clotting abnormalities
and may result in a trauma-induced coagulopathy (TIC).
Activation of protein C is central to TIC [2] and associ-
ated with increased fibrinolysis [3] and loss of fibrinogen
[4]. Hypofibrinogenaemia occurs early after injury and is
an independent predictor of death [5]. Augmentation of
blood fibrinogen levels necessitates the use of a concen-
trated form of fibrinogen supplementation (e.g., cryopre-
cipitate or fibrinogen concentrate [FgC]) because fresh
frozen plasma (FFP) alone is ineffective [4, 6].
There is continued debate about the comparative effect-
iveness of the two concentrated fibrinogen treatments [7,
8], despite two recent feasibility randomised controlled tri-
als (RCTs) in trauma haemorrhage (CRYOSTAT 1 [9] and
FiiRST [10]). The aim of this paper is to report the find-
ings of a second feasibility study in adult trauma haemor-
rhage using FgC. The primary objectives of the E-FIT 1
study were to determine whether it was possible to deliver
FgC therapy early (within 45 minutes) to adult trauma pa-
tients and the proportion of participants whose fibrinogen
levels were maintained ≥ 2 g/L during active haemorrhage.
Methods
Study design E-FIT 1 trial
The E-FIT 1 study was a multi-centre, double-blind,
placebo-controlled RCT conducted in five UK major
trauma centres. The study is registered with www.control-
led-trials.com (ISRCTN67540073).
Eligibility criteria and randomisation
Trauma patients were eligible if they were adults (judged
to be aged 16 years or older), were actively bleeding and
in haemorrhagic shock and therefore required activation
of the major haemorrhage protocol (MHP) or had already
received a transfusion of emergency red blood cells (RBC).
Exclusion criteria included patient transferred from an-
other hospital, the trauma team leader deemed the injury
incompatible with life, more than 3 hours had elapsed
from time of injury, pregnant women and severe isolated
or unsalvageable head injury. Women of childbearing age
had a point-of-care blood test performed to rule out preg-
nancy (Abbott, Princeton, NJ, USA).
Participants were block randomised in a 1:1 ratio of pla-
cebo to active arm. An independent statistician produced
the allocation sequence using a computer-generated ran-
dom sequence, and randomisation lists were produced
centrally. Allocation concealment was maintained by the
labelling of study packs prior to release to sites. Identical
study packs containing either FgC or placebo were se-
quentially labelled, and participants were allocated to the
next available study pack. All research site staff, partici-
pants and trial management staff were blinded to study
allocation.
Consent
An emergency waiver with independent agreement
process was used. Written informed consent from the par-
ticipant was sought as soon as practically possible after
study entry for continuation in the trial. If the participant
did not regain capacity, agreement was sought from the
participant’s next of kin or other appropriate representa-
tive. The protocol and consent process was approved by
the NHS National Research Ethics Service (NRES) Com-
mittee South Central Oxford C Ethics Committee (15/S3/
0316) and the Medicines and Healthcare products Regula-
tory Agency (MHRA) (25224/0003/001-0001).
Study intervention
Participants were randomised equally to treatment or pla-
cebo. All randomised participants received MHP, and the
study intervention was started as soon as possible and
within 45 minutes of hospital arrival. Typically an MHP
constituted two transfusion packs—pack 1 followed by re-
peated use of pack 2—until bleeding was controlled. Pack
1 included 4 RBC and 4 FFP; pack 2 included 4 RBC, 4
FFP, 10 U of cryoprecipitate (approximately 300 ml, 4 g of
fibrinogen) and 1 pool platelets. (Specifications for blood
components are found in the UK ‘red book’ [11]). Stand-
ard laboratory clotting tests were taken throughout active
bleeding, and a fibrinogen level of < 1.5 g/L was the trigger
for additional cryoprecipitate, when necessary.
The dose of FgC was chosen using data from the CRYO-
STAT 1 trial [9]. In this trial, two pools of UK cryoprecipi-
tate, containing approximately 4 g of fibrinogen,
constituted the study intervention, and fibrinogen levels
were maintained above 1.8 g/L during active bleeding.
Modelling data from a multi-centre European study have
demonstrated that a fibrinogen level of 2.3 g/L is associ-
ated with the lowest mortality rates [12]. A dose of 6 g of
FgC was therefore chosen because 2 g of fibrinogen raises
the blood level in patients with major bleeding by approxi-
mately 0.5 g/L [13].
In the treatment arm, an infusion of 6 g of FgC (RiaS-
TAP; CSL Behring, King of Prussia, PA, USA) was adminis-
tered as soon as possible, and an equivalent volume
(300 ml) 0.9% saline was administered in the placebo arm.
FgC and placebo were blinded interventions. Study inter-
vention packs were held in the emergency department
(ED). Blinding was maintained by research staff following a
validated protocol [14, 15]. Reconstitution of the study
intervention was completed at the patient’s bedside by
research staff. The intervention drug was drawn into black
syringes and infused as an intravenous bolus over
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5 minutes. Participants were deemed to have received the
study intervention if at least five whole syringes were
infused.
Outcomes
The primary outcome was the feasibility of administering
the study intervention within 45 minutes of admission, de-
fined by the proportion of all participants randomised
who started their infusion within that time. For this trial
to be successful, at least 90% of the participants were re-
quired to achieve this target. An additional primary out-
come was to determine the proportion of participants
whose fibrinogen level remained at 2 g/L or above during
active haemorrhage.
Secondary outcome measures were clinical and labora-
tory measures of efficacy and safety. Clinical outcomes
included mortality at 3, 6 and 24 hours, and 28 days
from admission; transfusion requirements, in numbers
of units, at 3, 6 and 24 hours; duration of organ support;
in-patient stay, including the intensive care unit/high-de-
pendency unit; and quality of life. Safety was measured
by symptomatic thrombotic events and arterial (e.g.,
myocardial infarction, stroke) and venous (e.g., pulmon-
ary embolism, deep venous thrombosis) events during
hospital stay. Laboratory measures included Clauss fi-
brinogen level at 2 hours after admission and at day 7
from admission. Standard MHP protocols in the UK rec-
ommend frequent blood samples every 30–60 minutes
during trauma haemorrhage [16] and were taken as
standard measurements.
Sample and data collection
Blood samples were drawn immediately upon admission
to the resuscitation room. Clauss fibrinogen measures
were analysed in the hospital coagulation laboratories, ac-
cording to standard operating procedures. Patient charac-
teristics, mechanism and severity of injury, and admission
physiology were collected and scored using the Abbrevi-
ated Injury Scale, Injury Severity Score and Glasgow
Coma Scale. Tranexamic acid and other haemostatic drug
administrations were recorded. Organ support was de-
fined using the composite time to complete organ failure
resolution score [17]. Organ failure was defined using the
Sequential Organ Failure Assessment score. Data on tim-
ing of transfusions, clear fluids and mortality were col-
lected in the first 24 hours. Measures to mitigate venous
thromboembolic risk were recorded weekly to day 28.
Symptomatic thromboembolic disease was categorised ac-
cording to standard clinical and/or radiological measures.
Quality of life (EQ-5D-5L) questionnaires were completed
upon discharge or day 28, whichever was the sooner. The
EQ-5D-5L descriptive systems index value was calculated,
allowing the five health dimensions to be converted into a
single numeric measure [18].
Sample size and data analysis
If the proportion of participants who received the study
intervention within 45 minutes from admission was
90%, a sample size of 40 would yield a 95% CI for this
estimate of between 76% and 97%. To allow for 20%
drop-out, the final sample size was chosen to be 48 par-
ticipants in total, with 24 participants per arm. All ana-
lyses were performed according to the intention-to-treat
principle and included all randomised participants.
Clinical and laboratory measures were compared using
Fisher’s exact test or the Mann-Whitney test for categor-
ical or continuous data, as appropriate. Normal linear re-
gression was used to assess whether fibrinogen at 2 hours
from admission was different between the two arms,
adjusting for values at admission. Normal linear regres-
sion, unadjusted for any other factors, was used to assess
whether fibrinogen at 7 days from admission was different
between arms. Residual plots from each normal linear re-
gression were examined for evidence of non-linearity,
skew or non-constant variance. Log-transformed fibrino-
gen would be used in the regression model(s) if any evi-
dence was found. All-cause mortality was estimated using
the Kaplan-Meier method and compared using the
log-rank test. Duration of organ support and hospital stay
were estimated using competing risks methods and com-
pared using Gray’s test. Death prior to the event of interest
was considered the competing risk.
Sensitivity analyses were conducted for the primary out-
comes, treating cases with missing time of administration
of the study intervention as administration within 45 mi-
nutes (best-case scenario) or as administration beyond
45 minutes (worst-case scenario) and treating cases with
missing fibrinogen at 2 hours from admission as achieving
(best-case scenario) or not achieving (worst-case scenario)
a level of at least 2 g/L. Except where specified, all analyses
were unadjusted, and there was no adjustment for mul-
tiple testing. All statistical tests were two-sided. All ana-
lyses were undertaken using SAS/STAT software version
9.4 (SAS Institute Inc., Cary, NC, USA).
An independent data monitoring committee monitored
all safety events throughout the study. All serious adverse
events were evaluated and classified independently by the
co-chief investigators, and any disagreements were re-
solved by consensus. The study manuscript was produced
according to Consolidated Standards of Reporting Trials
(CONSORT) recommendations for the reporting of ran-
domised clinical trials [19].
Results
Recruitment and baseline characteristics
Of 166 adult trauma patients with major trauma haem-
orrhage who were admitted and screened between Janu-
ary 2016 and November 2016, 78 met eligibility criteria
and 48 were randomised to the trial. The main reasons
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for ineligibility are set out in the CONSORT flow diagram
(Fig. 1). Of the 48 participants randomised, 39 received
study intervention. Of the nine who did not receive study
intervention, no intravenous access could be established in
two participants, and seven participants initially deemed eli-
gible were subsequently found not to meet eligibility cri-
teria: Three had no ongoing haemorrhagic shock
(stabilisation of blood pressure and heart rate), and four
were found to have unsalvageable traumatic brain injury.
No participant withdrew consent or was lost to follow-up.
One participant was screened and found to be ineligible
owing to concerns regarding potential pregnancy.
Baseline characteristics were similar in the two study
arms (Table 1), although participants in the FgC arm
had a lower systolic blood pressure (86 mmHg vs.
95 mmHg), higher injury severity (34 vs. 29), and lower
EXTEM clot amplitude at 5 minutes (26 mm vs. 35 mm)
on admission. All participants received a 1-g bolus of
tranexamic acid either pre-admission or upon arrival to
hospital. Mean admission fibrinogen level was 1.6 g/L
(SD, 0.7) in the FgC arm and 2.1 g/L (SD, 0.9) in the pla-
cebo arm (Table 2). No participant received platelets,
cryoprecipitate or colloid pre-admission.
Primary outcomes
Twenty-seven of 39 participants (69%; 95% CI, CI 52–83%)
across both arms received study intervention within 45 mi-
nutes of admission. It was not feasible to deliver study
intervention within 45 minutes of hospital admission, and
the pre-defined target of 90% compliance was not met. The
median time to delivery of study intervention was 39
minutes (IQR, 28.0–54.0) across all participants and was
similar in each arm (p = 0.56); in the FgC arm it was
37.5 minutes (IQR, 31.0–43.5), and in the placebo arm it
was 40.0 minutes (IQR, 23.0–76.0). Twelve participants did
not receive study intervention within 45 minutes, for the
following reasons: awaiting pregnancy results (n = 2), inabil-
ity to administer treatment whilst participant was in com-
puted tomography scanner (n = 4), lack of intravenous
access (n = 2), transfusion not commenced immediately
upon admission (n = 3), and clerical error regarding the
time when a participant was booked into the ED (n = 1).
Seventy-five percent (95% CI, 51–91%) of participants
in the FgC arm (15 of 20 participants) had a fibrinogen
blood level greater than or equal to 2 g/L during the first
2 hours of admission compared with 47% (95% CI, 23–
72%) in the placebo arm (8 of 17 participants) (p = 0.10).
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) flow diagram. Overall recruitment rate was 62% and ranged between 22% and
100% across the five centres. TBI Traumatic brain injury.
Curry et al. Critical Care  (2018) 22:164 Page 4 of 9
The levels changed over time, as shown in Table 2. The
mean fibrinogen level was higher in the FgC arm than in
the placebo arm (p < 0.0001) at 2 hours from admission
during active haemorrhage. In the placebo group, the fi-
brinogen level fell by 0.2 g/L (SD, 0.5), compared with a
rise of 0.9 g/L (SD, 0.5) in the active arm. Sensitivity ana-
lyses of primary outcome measures revealed that the re-
sults presented were not sensitive to the missing data.
There was no evidence of a difference in Clauss fibrinogen
levels at day 7 between arms (p = 0.28). There was no evi-
dence of non-linearity, skew or non-constant variance in
any of the normal linear regression residual plots.
Secondary outcomes including safety
There was no difference in transfusion requirements be-
tween arms (Table 3) in the first 24 hours for RBC, FFP
and platelets, but we observed a trend towards more
cryoprecipitate use in the FgC arm at 24 hours (p =
0.06). There were ten deaths in the FgC arm and seven
in the placebo arm (Fig. 2), and six participants died
prior to receipt of study intervention (two in the FgC
arm and four in the placebo arm). All-cause mortality at
28 days was 35.5% (95% CI, 23.8–50.8%) overall, 42.0%
(95% CI, 25.2–64.0%) in the FgC arm and 29.2% (95%
CI, 15.1–51.6%) in the placebo arm. Of the 11 partici-
pants who died after receiving the study intervention,
three died of uncontrolled bleeding (two FgC), five died
of multiple organ failure (four FgC), one died of single
organ failure (FgC), one died of traumatic brain injury
(FgC) and one died of polytrauma (placebo). The times
to death for the participants who died of haemorrhage
were 1.9 and 4.9 hours (FgC) and 8.1 hours (placebo).
We did not observe any difference in duration of
organ support (median 17 days in both arms, p = 0.63),
overall hospital length of stay (lower quartile 27 and
18 days [FgC vs. placebo], p = 0.49) or quality of life (me-
dian self-evaluated health scores, 48 and 55 [FgC vs. pla-
cebo], p = 0.39; median index values, 0.16 and 0.21 [FgC
Table 1 Baseline characteristics
Fibrinogen concentrate arm Placebo arm
Subjects
No. 24 24
Age, yr 38 (31–47) 36 (22–56)
Male, n (%) 20 (83) 19 (79)
Timelines
Injury to hospitala, min 98 (77–118) 87 (66–116)
Injuries and admission physiologic measures
Blunt 21 (88) 18 (75)
ISS 34 (24–43) 29 (22–34)
Systolic blood pressure, mmHg 86 (72–124) 95 (82–128)
Heart rate, beats/min 101 (88–116) 112 (93–126)
GCS 3 (3–14) 3 (3–15)
Clauss fibrinogen level, g/L 1.9 (0.9–2.2) 2.3 (1.6–2.5)
EXTEM CA5 26 (15–28) 35 (26–42)
FIBTEM CA5 4 (3–7) 7 (4–12)
Pre-randomisation
TXA administered pre-admission 18 (75) 20 (83)
RBC, units 1 (0–2) 1 (0–2)
FFP, units 0 (0–1) 0 (0–2)
Crystalloids, ml 0 (0–475) 0 (0–625)
Abbreviations: CA5 Clot amplitude at 5 min, FFP Fresh frozen plasma, GCS Glasgow Coma Scale, ISS Injury Severity Score, RBC Red blood cells, TXA Tranexamic acid
Data are number (%) for categorical variables and median (IQR) for continuous variables
aOne participant was admitted to hospital > 3 h after injury (subsequently defined as a protocol deviation)
Table 2 Fibrinogen levels over time, by treatment arm
Outcome Fibrinogen
concentrate
arm (n = 24)
Placebo arm
(n = 24)
Overall
(n = 48)
p Value
Fibrinogen, mean (SD)
At admission 1.6 (0.7) 2.1 (0.9) 1.9 (0.8) n/a
At 2 h from admission
during first active
haemorrhagea
2.8 (1.3) 1.8 (0.6) 2.3 (1.1) < 0.0001
7 days from
admission
6.7 (1.8) 7.5 (1.9) 7.1 (1.9) 0.2843
aP value adjusted for value at admission
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vs. placebo], p = 0.92). Eighty-three percent of partici-
pants (39 of 47) received venous thromboembolism pre-
vention therapy by day 7 of their hospital admission,
rising to 100% by day 28 (15 of 15). Serious adverse
events are described in Table 4. Five patients experi-
enced a thromboembolic event; two of the three arterial
events occurred in the placebo arm, and two pulmonary
embolic events occurred in the FgC arm.
Discussion
This is the second RCT evaluating administration of FgC in
trauma. Despite median administration times approximat-
ing 40 minutes, the range varied widely (10 to 82 minutes),
and only 69% of participants received study intervention
within 45 minutes of admission. There was some evidence
of a difference in the proportion of participants with fi-
brinogen levels ≥ 2 g/L between arms (p = 0.10). However,
the FgC group had a fibrinogen level of 1.6 g/L on admis-
sion (0.7 g/L lower than the placebo arm), which likely re-
flects the trends towards higher injury severity and greater
degree of shock in the intervention arm. Importantly, the fi-
brinogen level in the FgC arm rose by a mean of 0.9 g/L
(SD, 0.5) compared with a reduction of 0.2 g/L (SD, 0.5) in
the placebo arm, and average fibrinogen level at 2 hours
from admission was significantly higher in the FgC arm (p
< 0.0001). Fibrinogen levels did not remain elevated by
7 days, a finding also shown in the two other feasibility
RCTs [9, 10], suggesting no long-term effect of fibrinogen
replacement.
Transfusion requirements were not different between
arms; however, it was notable that there was a trend to-
wards increased cryoprecipitate use in the FgC arm.
Transfusion needs were greater for all blood components
in the FgC arm, again a difference likely reflecting the
higher injury burden and shock, the empiric nature of
transfusion administration, and the lower admission level
of fibrinogen. The proportion of patients achieving
haemostasis at 3 hours, however, was identical in both
arms, suggesting that duration of bleeding does not fully
explain the need for greater cryoprecipitate use in the FgC
arm (data not shown).
No safety signal for thrombotic events was detected in
this study. Venous thromboembolism was reported only
in the FgC arm and was under 10%, a rate similar to that
in a recent FgC trauma study in which researchers also
used 6 g of FgC as their intervention [10]. More deaths
were recorded in the FgC arm (n = 8 vs. n = 3), with no
difference in deaths resulting from bleeding between
arms, although the study was not powered for mortality.
Differences in death rates may represent the variability
in baseline characteristics between groups (i.e., higher
injury severity and worse organ failure in the FgC arm).
Rapid reconstitution is often cited as an important
benefit of FgC. Our study, and that of Nascimento et al.
[10], reported similar median FgC reconstitution times:
23 minutes (SD, 9) (E-FIT1) and 26 minutes (SD, 5)
(FiiRST). In a non-RCT setting, dissolution of fibrinogen
for in vitro testing has been reported within 30 seconds
[20], although it most commonly takes 10 minutes [21].
The longer reconstitution times in our study were due
Table 3 Transfusion requirements during the first 24 hours
Fibrinogen concentrate
arm (n = 24)
Placebo arm
(n = 24)
p Value
Units at 3 h
RBC 4 (2–6) 2 (2–6) 0.73
FFP 3 (2–6) 3 (0–7) 0.92
Platelets 0 (0–1) 0 (0–1) 0.98
Cryoprecipitate 0 (0–2) 0 (0–1) 0.46
Units at 6 h
RBC 3 (2–6) 2 (2–5) 0.62
FFP 4 (2–6) 3 (0–7) 0.77
Platelets 0 (0–1) 0 (0–1) 0.85
Cryoprecipitate 0 (0–2) 0 (0–0) 0.12
Units at 24 h
RBC 4 (2–8) 2 (2–5) 0.38
FFP 5 (2–8) 3 (0–6) 0.39
Platelets 1 (0–1) 0 (0–1) 0.59
Cryoprecipitate 2 (0–2) 0 (0–0) 0.06
FFP Fresh frozen plasma, RBC Red blood cells
Data are median (IQR). At each time point blood component use was analysed
for patients who were still alive within the specified time frame. One
participant died within 2 h (± 30 min) of admission, two within 3 h (± 30 min)
of admission, five within 6 h (± 1 h) of admission and seven within 24 h (± 4 h)
of admission
Fig. 2 Survival to day 28, by treatment arm
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to the need to dissolve the fibrinogen whilst maintaining
allocation concealment. The study vials were kept in
cardboard tamper-proof boxes, meaning that dissolution
of fibrinogen powder (or placebo) could not be visually
assessed and that each vial needed to ‘rest’ for 3 minutes
prior to being drawn into a syringe [14]. In an unblinded
RCT, time to factor concentrate administration was
shorter at 10 minutes (IQR, 10–16) [22]. A future alter-
native source of concentrated fibrinogen may be ex-
tended shelf-life cryoprecipitate [23], which could be
pre-thawed and held in the ED, avoiding reconstitution
times, but this has yet to be tested in an RCT setting.
The inclusion criteria for this trial did not use fibrinogen
level. Goal-directed transfusion therapy using viscoelastic
haemostatic assays (VHAs) (thromboelastography or rota-
tional thromboelastometry [ROTEM]) is standard practice
in many trauma centres in Europe and the United States
[22, 24, 25], and it is advocated for guiding transfusion ther-
apy. In a retrospective European study, VHA-guided ther-
apy has led to a 50% reduction in the incidence of massive
transfusions for trauma compared with that predicted by
the trauma-associated severe haemorrhage score, with an
associated reduction in mortality from 33% to 22% [26].
However, delays to first results are incurred (on average,
15–20 min [21, 22]), and empiric, immediate transfusion
therapy for patients with uncontrolled haemorrhage is a
standard of care [27]. To date, in trauma haemorrhage,
there are no evidence-based thresholds to guide fibrinogen
treatment, only expert consensus [28]. A small RCT, which
was terminated early, used dual ROTEM measures to guide
transfusion (FIBTEM A10 > 8 mm, EXTEM CT < 78 sec-
onds), and these data may support the use of ROTEM to
direct transfusion therapy [22] but need validation in a lar-
ger study. A large European study is due to be completed
in 2018 (iTACTIC; ClinicalTrials.gov, NCT02593877)
which will compare the efficacy of VHA and standard clot-
ting tests for transfusion in trauma.
Our study was designed to include participants with
the clinical phenotype of severe bleeding, not those ex-
clusively with a low fibrinogen level. We did not use
VHA or Clauss fibrinogen for two reasons: (1) to min-
imise delay to randomisation (VHA testing incurs 10–
Table 4 Serious adverse events
Fibrinogen concentrate arm Placebo arm
Subjects
Number of participants in receipt of the study intervention 20 19
Number of participants experiencing at least one SAEa 13 11
Number of SAEs 29 21
Symptomatic thrombotic events 3 2
Arterial
MI 0 0
Stroke 1 1
Other (arterial thrombus) 0 1
Venous
DVT 0 0
PE 2 0
Sepsis 4 6
Organ failure 10 2
Multiple organ failure 4 1
Single organ failure 6 1
New-onset major bleeding 1 3
Uncontrolled major bleedingb 2 1
Other SAEs 9 7
Death
All deathsc 8 3
Death due to bleeding 2 (25%) 1 (33%)
Abbreviations: DVT Deep venous thrombosis, MI Myocardial infarction, PE Pulmonary embolus, SAE Serious adverse event
Safety data were collected for only the 39 participants who were administered the study intervention
aEleven participants experienced more than one SAE
bMajor bleeding that was not controlled at any time from admission
cIncludes all cases of multi-organ failure, all cases of uncontrolled bleeding, one case of single organ failure in the active treatment arm and two other SAEs (one
in the active treatment arm and one in the placebo arm)
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15-min delays) when speed of delivery of transfusion is
known to be important [27, 29, 30] and (2) to include
participants with the broader clinical entity of bleeding.
The recent RETIC trial used FIBTEM A10 for eligibility,
and randomisation took approximately 35–38 minutes,
compared with 15–16 minutes in our study [22].
This is one of the first published multi-centre UK
trauma transfusion studies, and it provides evidence that
the delivery and conduct of RCTs in the challenging envir-
onment of the ED is possible. Prior to study start it was
predicted that the recruitment would take 18 months. Re-
cruitment was completed within 10 months, facilitated
both by the research infrastructure and by the ability of re-
search teams to recruit outside core hours. Rapid recruit-
ment has recently been seen in another transfusion
trauma study (FEISTY; ClinicalTrials.gov, NCT02745041)
showing an encouraging appetite for the collection of
high-quality collaborative study data.
This study has several limitations. It is a small feasibility
study, and large differences were seen between treatment
groups, in particular shock parameters and fibrinogen
levels, which will alter treatment effects. Treatments for
trauma haemorrhage are more effective when given earlier
in the time course of major bleeding, as demonstrated by
the CRASH-2 data [29], and it is possible that a time delay
incurred in the delivery of FgC in this study may have at-
tenuated potential clinical benefits. This study was de-
signed to test the ability of the research teams to
administer FgC rapidly, and secondary endpoints should
be viewed cautiously because the study was not powered
for evaluation of clinical outcomes.
Conclusions
E-FIT 1 shows that it was not feasible to administer the
study intervention within 45 minutes of admission con-
sistently, and the pre-defined target of 90% participants
was not met. Although the proportion of participants with
fibrinogen levels above 2 g/L was not statistically different
between arms, the rise in fibrinogen levels was greater in
the active arm. There was no safety signal for thrombotic
events in this study. This trial has highlighted the need for
future studies to focus on the barriers to rapid delivery of
concentrated fibrinogen therapies by examining each step
in the trial process, including times taken to confirm eligi-
bility and subsequent randomisation, as well as the
specifics of speed of drug reconstitution and delivery.
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